A Phase 1 Safety And Pharmacokinetic Study Of SU011248 And Capecitabine In Patients With Advanced Solid Tumors

NCT00618124 Phase 1 COMPLETED

This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors

Details

Lead sponsor	Pfizer
Phase	Phase 1
Status	COMPLETED
Enrolment	77
Start date	2005-05
Completion	2008-07

Conditions

• Solid Tumors
• Breast Cancer
• Neoplasms

Interventions

• SU011248; Capecitabine

Primary outcomes

• To determine the maximally tolerated dose of SU011248 (dosed continuously or on a 4/2 or 2/1 Schedule) when given in combination with capecitabine. — From Screening until disease progression or discontinuation of the study

Countries

United States